BIOSIG TECHNOLOGIES, INC.


Associated tags: ECG, PURE, Nautilus, Inc. v. Biosig Instruments, Inc., Electrophysiology, Physician, Security (finance), COVID-19, Mayo Clinic, Pharmaceutical industry, Journal, Journal of Cardiovascular Electrophysiology, Patient, Medical device, Arrhythmia, EP, Online, Wiley (publisher)

Locations: UNITED STATES, JAPAN, ARIZONA, MINNESOTA, LOUISIANA, NEW ORLEANS, SWITZERLAND, FINLAND, WESTPORT, CT, US

BioSig Announces Reduction of its Workforce

Retrieved on: 
Tuesday, February 20, 2024

Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.

Key Points: 

Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.

BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases

Retrieved on: 
Tuesday, February 6, 2024

Available by subscription, PURE EP™’s NFT algorithm monitors changes in the local unipolar electrogram, empowering electrophysiologists with tissue-specific feedback and color-coded characterization in real time.

Key Points: 
  • Available by subscription, PURE EP™’s NFT algorithm monitors changes in the local unipolar electrogram, empowering electrophysiologists with tissue-specific feedback and color-coded characterization in real time.
  • Since its launch in Q4 2023, the software has been leveraged at some of the largest and leading medical centers and health systems in the country.
  • Researchers from Cleveland Clinic presented topline clinical findings on the value of NFT at the Heart Rhythm 2023 convention held last May.
  • To learn more about PURE EP™’s growing suite of proprietary software-based features, click here .

BioSig Announces Reverse Stock Split

Retrieved on: 
Wednesday, January 31, 2024

The new CUSIP number for the common stock following the reverse stock split will be 09073N3008.

Key Points: 
  • The new CUSIP number for the common stock following the reverse stock split will be 09073N3008.
  • At the effective time of the reverse stock split, every ten shares of BioSig's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share.
  • It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
  • The reverse stock split will have no effect on the number of authorized shares of common stock or the par value per share.

BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy

Retrieved on: 
Tuesday, January 30, 2024

Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to reduce annual cash burn by 50%.  The Company is reducing its internal workforce, which is expected to be completed by January 31. The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.

Key Points: 
  • The Company is reducing its internal workforce, which is expected to be completed by January 31.
  • The Company is also shifting its business model and seeks to partner with organizations for sales distribution and clinical support of its PURE EP™ Platform.
  • "BioSig is at an important juncture, and we are taking steps to streamline our corporate structure.
  • Their hard work and dedication were integral to bringing the PURE EP™ Platform to where it is today," said Ken Londoner, Chairman and CEO of BioSig.

BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024

Retrieved on: 
Wednesday, December 6, 2023

Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.

Key Points: 
  • Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.
  • In the letter, Kenneth Londoner, Chairman & CEO of BioSig, states “BioSig’s capacity for innovation is stronger than ever, and to our knowledge, our opportunities for sustainable growth are achievable….
  • We expect to deliver significant progress in the year ahead.”
    Topics discussed in the letter include:
    The latest PURE EP™ software features and functionality that, to our knowledge, no other intracardiac signaling technology provides.
  • To read the letter in its entirety, please visit ir.biosig.com/presentations .

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, November 13, 2023

The gross proceeds from the offering were approximately $2.5 million before deducting the placement agent’s fees and estimated offering expenses.

Key Points: 
  • The gross proceeds from the offering were approximately $2.5 million before deducting the placement agent’s fees and estimated offering expenses.
  • BioSig intends to use the net proceeds of this offering for working capital and general corporate purposes.
  • The securities described above were offered by BioSig pursuant to a shelf registration statement on Form S-3 (File No.
  • The securities offered in the registered direct offering were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Thursday, November 9, 2023

The gross proceeds from the offering are expected to be approximately $2.5 million.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $2.5 million.
  • BioSig intends to use the net proceeds of this offering for working capital and general corporate purposes.
  • The securities described above are being offered by BioSig pursuant to a shelf registration statement on Form S-3 (File No.
  • The securities offered in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP

Retrieved on: 
Tuesday, November 7, 2023

Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.

Key Points: 
  • Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.
  • Since April 2022, he has served on the BioSig Board of Directors and as Chairman of the nominating and corporate governance committee.
  • “Fred is well-known as a key executive leader in the global medical device industry.
  • Mr. Hrkac currently serves on the board of Serres in Helsinki, Finland, and Spineart in Geneva, Switzerland as chairman of the board.

BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care

Retrieved on: 
Thursday, November 2, 2023

Harnessing the power of automation, PURE EP™’s latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures.

Key Points: 
  • Harnessing the power of automation, PURE EP™’s latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures.
  • "Our commitment to innovation and delivering exceptional patient care drives our ongoing collaboration with BioSig,” said Hicham El Masry, M.D., FHRS, Cardiac Electrophysiologist at Mayo Clinic-Phoenix.
  • “The integration of PURE EP™'s advanced software features further reinforces our dedication to providing the best possible healthcare solutions for our patients.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI

Retrieved on: 
Wednesday, November 1, 2023

Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are pleased to add five  utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad.

Key Points: 
  • Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are pleased to add five  utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad.
  • Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP™ Platform.”
    U.S. Patent Application No.
  • 11,737,699 granted on August 29, 2023 and is entitled “Systems and Methods for Performing Electrophysiology (EP) Signal Processing.” The patent describes and claims methods and systems for producing a clean unipolar signal.
  • 1 allowed and 1 pending U.S. patent applications directed to artificial intelligence (AI)